Mepolizumab Overview

Introduction of Mepolizumab

Mepolizumab (SB-240563) is a high-affnity, humanized monoclonal antibody of the IgG1/κ subtype, specifc for Interleukin-5(IL-5). Mepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma in patients aged 12 years and older. It was approved by the FDA in November, 2015 for the treatment of asthma under the brand name Nucala (marketed by GlaxoSmithKline). Additional, mepolizumab has been investigated in the treatment of severe nasal polyposis, among numerous other conditions.

Mechanism of Action of Mepolizumab

As eosinophils are the dominating effector cells in asthma, inhibition of eosinophilia, theoretically would result in a decreased airway injury, mucus hypersecretion and bronchial hyper-responsiveness. IL-5 induces an inflammatory response by interacting with eosinophils through targeting the Interleukin-5 receptor (IL-5R) expressed in eosinophils, basophils and some mast cells. Mepolizumab is a fully humanized mAb specific for human IL-5, which blocks binding of human IL-5 to the α chain of the IL-5R complex, thus inhibits bioactivity of IL-5. Blocking of IL-5 signalling thereby reduces the production and survival of eosinophils and inhibits eosinophilic-driven inflammation.

Figure 1 Mechanism of Action of Mepolizumab

Clinical Projects of Mepolizumab *

Approved Drugs of Mepolizumab **

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
NUCALA	Refractory eosinophilic asthma	Injection, powder for	100mg	Subcutaneous	GlaxoSmithKline Australia Pty Ltd	February 2, 2016
NUCALA	Severe asthma	Injection, powder for	100 mg/mL	Subcutaneous	GlaxoSmithKlineLnc	October 14, 2015
NUCALA	Refractory eosinophilic asthma	Injection, powder for	100mg	Subcutaneous	GlaxoSmithKlineLnc	March 14, 2016

What We Provide

Therapeutic Antibody

Mepolizumab

We provide high-quality Mepolizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Mepolizumab&cntry=&state=&city=&dist=

** Information presented in the table were collected from the following websites:
http://search.tga.gov.au/s/search.html?collection=tgaartg&profile=record&meta_i=232028
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125526Orig1s000SumR.pdf
https://www.drugbank.ca/drugs/DB06612

For research use only. Not intended for any clinical use.